Beyond Air Stock (NASDAQ:XAIR)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$0.19

52W Range

$0.15 - $0.68

50D Avg

$0.19

200D Avg

$0.33

Market Cap

$19.30M

Avg Vol (3M)

$3.34M

Beta

0.23

Div Yield

XAIR Company Profile

Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

107

IPO Date

Jun 12, 2018

Website

XAIR Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Mar 25	Mar 24
Business Segment	$5.37M	$1.16M

Fiscal year ends in Mar 24 | Currency in USD

XAIR Financial Summary

	Mar 24	Mar 23	Mar 22
Revenue	$1.16M	-	-
Operating Income	$-63.01M	$-51.50M	$-40.71M
Net Income	$-60.24M	$-55.82M	$-43.18M
EBITDA	$-59.03M	$-58.20M	$-42.70M
Basic EPS	$-0.91	$-0.93	$-0.84
Diluted EPS	$-0.91	$-0.93	$-0.84

Fiscal year ends in Mar 24 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Jun 17, 25 | 4:30 PM

Q3 25Feb 10, 25 | 4:30 PM

Q2 25Nov 11, 24 | 4:30 PM

Peer Comparison

Ticker	Company
MXCT	MaxCyte, Inc.
CLPT	ClearPoint Neuro, Inc.
PAVM	PAVmed Inc.
TELA	TELA Bio, Inc.
TARA	Protara Therapeutics, Inc.
PDSB	PDS Biotechnology Corporation
XFOR	X4 Pharmaceuticals, Inc.